Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis -- focus on subcutaneous tocilizumabPotential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical reviewManagement of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerationsBiologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.A new alternative therapy in dermatology: tocilizumab.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.
P2860
Q24185797-147878CC-651F-42D4-B93B-F5CD15F94F4AQ27023091-99C66A75-C76A-4D3F-8EFF-75E858F0223EQ27024465-25F50503-E038-4938-B1E1-7B3F0CF1AF10Q35618458-06C0072C-6DCF-4975-B656-5531620847BFQ36195284-41006A90-D555-4683-BED0-FB2BEA48EEDEQ38285827-A2802EE1-4E90-45E2-AB99-EAB80F21F956Q38411334-A7717675-1BBC-4210-9F47-E3BC3D5334ADQ38507301-1C3BE0C4-7118-4C04-A0DD-0A48C3DD93C7Q38540353-19D5AF4B-3F34-4B88-A2F5-C30203AEFCD9Q40167433-BE14403F-21DF-46FE-8F59-921B7679F386Q51627957-61882CA5-A43F-40EE-B41F-D699004A756F
P2860
Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mechanism-based approach using ...... thetic DMARDs (MATSURI study).
@en
Mechanism-based approach using ...... e response to synthetic DMARDs
@nl
type
label
Mechanism-based approach using ...... thetic DMARDs (MATSURI study).
@en
Mechanism-based approach using ...... e response to synthetic DMARDs
@nl
prefLabel
Mechanism-based approach using ...... thetic DMARDs (MATSURI study).
@en
Mechanism-based approach using ...... e response to synthetic DMARDs
@nl
P2093
P2860
P356
P1476
Mechanism-based approach using ...... thetic DMARDs (MATSURI study).
@en
P2093
Eisuke Shono
Eriko Tarumi
Kimio Terao
Masato Imai
Midori Suzaki
Seiji Mogi
Shuji Ohta
Tomomi Tsuru
Yoshimasa Ishida
P2860
P304
P356
10.1002/JCPH.185
P577
2013-10-12T00:00:00Z